Drug
Besifloxacin clinical trials
Also written Besivance, ISV-403 and BOL-303224.
- studies test it
- 17
- open now
- 0
- in phase 3
- 6
- first study started
- 2004
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
17 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 6
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 5
Bausch & Lomb Incorporated (11) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Frank A. Bucci, Jr., M.D. (1) · Johns Hopkins University (1) · John, George, M.D. (1) · Ophthalmology Consultants, Ltd. (1) · Cornea Consultants Of Nashville (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses besifloxacin is read from its arms, and is right about nine times in ten.
Testing it · 17
- Besifloxacin in Bacterial KeratitisCompletedNot applicableMcGill University Health Centre/Research Institute of the McGill University Health CentreNCT02497365Written as Besifloxacin
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing PhacoemulsificationCompletedPhase 4Frank A. Bucci, Jr., M.D.NCT01296191Written as besifloxacin
- Study of Ocular Penetration of Topically Administered FluoroquinolonesCompletedPhase 4Johns Hopkins UniversityNCT00924729Written as Besifloxacin 0.6% ophthalmic suspension
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.TerminatedPhase 2Cornea Consultants Of NashvilleNCT01928693Written as Besivance 0.6% Ophthalmic Suspension
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisCompletedPhase 3Bausch & Lomb IncorporatedNCT00348348Written as Besifloxacin
- Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisCompletedPhase 2Bausch & Lomb IncorporatedNCT00622908Written as ISV-403
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.CompletedPhase 3Bausch & Lomb IncorporatedNCT00347932Written as ISV-403
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisTerminatedPhase 3Bausch & Lomb IncorporatedNCT01740388Written as Besifloxacin
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial ConjunctivitisTerminatedPhase 3Bausch & Lomb IncorporatedNCT01330355Written as Besivance
- Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute BlepharitisCompletedPhase 4John, George, M.D.NCT01478256Written as Besifloxocin
- Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleCompletedPhase 3Bausch & Lomb IncorporatedNCT01175590Written as Besivance
- Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 DaysCompletedPhase 1Bausch & Lomb IncorporatedNCT01120418Written as Besifloxacin Ophthalmic Suspension 0.6%
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisCompletedPhase 2/3Bausch & Lomb IncorporatedNCT00972777Written as Besifloxacin
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of SubjectsCompletedPhase 1Bausch & Lomb IncorporatedNCT00824070Written as Besifloxacin hydrochloride
- Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical InstillationCompletedPhase 1Bausch & Lomb IncorporatedNCT00905762Written as Besifloxacin
- Systemic Pharmacokinetics of BOL-303224-ACompletedPhase 1Bausch & Lomb IncorporatedNCT00407589Written as BOL-303224-A
- 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract SurgeryCompletedPhase 4Ophthalmology Consultants, Ltd.NCT01455233Written as besivance
Codes
What other systems call besifloxacin · ClinicalTrials.gg INT005141
- MeSH (NLM) C522124besifloxacinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BFE2NBZ7NXBESIFLOXACINConfirmed FDA, NLM, Wikidata
- RxNorm 819911Confirmed FDA, Wikidata
- Wikidata Q3638978BesifloxacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83553BesifloxacinOne source FDA
- DrugBank DB06771One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522124 | besifloxacin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BFE2NBZ7NX | BESIFLOXACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 819911 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3638978 | Besifloxacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83553 | Besifloxacin | One source FDA |
| DrugBank | DB06771 | — | One source Wikidata |
Also registered as besifloxacin hydrochloride (UNII 7506A6J57T).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.